Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)

NCT03061812 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

444

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Rovalpituzumab tesirine
DRUG: Topotecan
DRUG: Dexamethasone

Sponsor

AbbVie